The retaliatory division of the Department of Justice brought the case to a federal court in Pennsylvania, alleging that Teva Pharmaceuticals USA engages in anticompetitive conduct, which resulted in consumers being paid at least $ 350 million.
Prosecutors accused the company of fixing prices, manipulating bids and allocating clients to three separate conspiracies, including pravastatin, a commonly prescribed cholesterol drug with the brand name Pravachol. A second conspiracy involved pricing on drugs used to treat arthritis, seizures, pain, skin conditions, and blood clots, the Justice Department alleged. The department said the third alleged plot involved treatment of brain cancer, cystic fibrosis, arthritis and high blood pressure.
Prosecutors alleged that Teva participated in the conspiracies from May 2013 until at least December 2015.
Assistant Attorney General Makan Delrahim, the top counterparty officer of the judicial department, said, “Today’s allegation suggests that no company has a huge conspiracy to play a role in the conspiracies, leading to increased dependence on millions of Americans for generic drugs . ” a statement.